BVS · XBRL financial data

Bioventus financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (BVS's year ends in late December)

In millions of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	431	512	512	573	568
Cost of goods and services sold	128	181	184	185	180
Gross profit	303	331	328	388	388
Research and development	19	26	13	14	12
Selling, general and administrative	254	333	304	341	314
Operating income (loss)	12	(251)	(82)	(12)	54
Other income (expense)	(3)	13	1	2	(1)
Income tax expense (benefit)	(2)	(51)	0	(5)	(2)
Net income (loss)	19	(159)	(156)	(34)	23
Earnings per share, basic USD per share	(0.15)	(2.59)	(2.49)	(0.52)	0.34
Earnings per share, diluted USD per share	(0.15)	(2.59)	(2.49)	(0.52)	0.33
Weighted average shares, basic millions of shares	45	61	63	65	67
Weighted average shares, diluted millions of shares	45	61	63	65	69

Fiscal years (BVS's year ends in late December)

In millions of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	44	32	37	42	51
Accounts receivable	125	137	123	127	128
Inventory	62	85	91	92	82
Prepaid and other current assets	27	19	17	14	11
Total current assets	263	273	268	276	273
Property and equipment, net	23	28	—	—	—
Right-of-use asset	17	17	13	7	5
Goodwill	148	14	7	7	7
Total assets	1,226	1,373	811	728	684
Accounts payable	17	38	23	24	11
Accrued liabilities	131	112	120	136	130
Current portion of long-term debt	18	33	28	27	15
Total current liabilities	181	304	175	210	160
Long-term debt	340	385	367	308	279
Lease liability, non-current	15	15	11	7	4
Total liabilities	692	1,032	590	542	455
Accumulated deficit	(7)	(165)	(322)	(355)	(335)
Total stockholders' equity	459	317	174	148	184
Total liabilities and equity	1,226	1,373	811	728	684

Fiscal years (BVS's year ends in late December)

In millions of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	19	(159)	(156)	(34)	23
Stock-based compensation	20	18	3	10	13
Depreciation and amortization	35	67	57	50	47
Net cash from operating activities	23	(14)	15	39	75
Purchases of property and equipment	7	10	7	1	3
Net cash from investing activities	(284)	(116)	16	23	(3)
Proceeds from issuing common stock	2	6	1	2	2
Net cash from financing activities	273	62	(27)	(55)	(62)
Net change in cash	12	(67)	5	5	10

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Bioventus	31	142	21*	not reported	—	Q3 FY26 10-QSep 26, 2026
Treace Medical Concepts	13	45	(4.7)*	65.0M	9.7 quarters	Q2 FY26 10-QJun 30, 2026
SS Innovations International	14	not reported	(4.2)*	200.4M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
SANUWAVE Health	9.4	9.7	0.4*	8.6M	—	Q2 FY26 10-QJun 30, 2026
Cerus	16	58	3*	202.0M	—	Q3 FY26 10-QSep 30, 2026
NeuroPace	13	23	(3.9)*	34.3M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
Electromed	20	19*	3*	8.4M	—	Q4 FY26 10-KJun 30, 2026
Tactile Systems Technology	75	92	12*	22.4M	—	Q3 FY26 10-QSep 30, 2026
Orasure Technologies	161	31	(9.9)*	69.0M	16.2 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.